TMDXNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
TransMedics Group, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$71.60+0.82 (+1.16%)
Close on Oct 19, 2026
- Market cap
- $2.91B
- P/E (TTM)
- 18.6
- Dividend yield
- 0.00%
TransMedics Group, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product revenue [Member] | $407.20M | $392.14M | $372.40M | $346.96M | $325.14M | $300.78M | $273.87M | $250.79M | $232.67M | $203.40M | $176.07M | $149.27M | 60.9% | +25.2% |
| Cost of service revenue | $261.27M | $243.75M | $233.09M | $219.40M | $206.15M | $187.45M | $167.67M | $150.30M | $126.09M | $93.52M | $65.55M | $42.56M | 39.1% | +26.7% |
| Service Unrelated to OCS Transplant [Member] | $4.50M | $4.50M | $4.10M | $4.20M | $4.30M | $4.40M | $4.40M | – | – | – | – | – | 0.7% | +4.7% |
| Unrelated to OCS Transplant [Member] | – | – | – | – | – | $4.40M | $4.40M | $5.80M | $6.90M | $5.80M | $4.90M | – | – | – |
By region
From the segment and revenue-disaggregation notes of TransMedics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.